• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
181808 165 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  # V# ]2 y$ V* r8 Q1 c6 E
9 z9 d( N" w3 F2 B0 s
6 Z3 ?) ?; g) ^4 P8 P+ B
Sub-category:
: U* f& G% n. q# F6 aMolecular Targets
- O# K" k$ i3 A  f/ }# X6 c
% d6 a4 B2 L! F( l7 a
2 a3 q/ w, n) Z. D* HCategory:& }/ r6 f! q7 p  B9 w
Tumor Biology
3 u- ?' c) y; T/ \: @7 b# L" s  r  @- u) M" K  R' n

8 R/ Z- I. ^2 t8 \1 |Meeting:6 G& h: o, L  X' |3 g0 ^
2011 ASCO Annual Meeting 9 e9 C0 P- j0 C: T, i8 t. I

7 G0 E) h3 J: }7 r) H
# W% d7 F6 J$ S0 E! oSession Type and Session Title:- q  X0 ?9 ]. i8 ^+ C/ B6 X: x
Poster Discussion Session, Tumor Biology . C7 n. w7 C& F$ Q
5 F' ?' R3 Y* G9 V
/ [" [2 W8 t6 o* |1 e; q
Abstract No:) |- a4 F0 C5 H5 N/ L1 f
10517
% o# o. R4 k7 [4 Z5 J, D) F& ~3 C2 B& A% H2 t. q8 Y. r4 {, c
* Q4 b& }$ {- X3 W
Citation:
3 F( Y& s* a/ f$ D5 lJ Clin Oncol 29: 2011 (suppl; abstr 10517)
' G/ C: f5 u% E8 U' w
/ ?* a$ m+ g4 R' d4 ^9 q6 l2 U0 d" B  v0 W
Author(s):! N1 M" K  t  I( u4 W  _5 {
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ; ^2 i# N- Z/ q% s( U! I+ J
( q$ ~/ s, A7 s/ G% C8 C
) ]. B* g  l' [! a7 g4 A, l
8 h1 s- }( F5 c- i
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings." |+ L* @( r4 F! m1 A. i( j

$ z% G0 C! H" M7 J& I7 c& QAbstract Disclosures
, B  ~/ a: v* @$ E: T9 n0 G  a
Abstract:
6 z- C( j* L: o0 S
: g0 [' k) m" a4 U; Y3 Q0 ]" F* X! p9 ]9 z6 N. a
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation." Z7 {/ @5 |9 m6 U9 l. z5 W

  ]% k  r+ i3 D* C" {0 Y $ _; {6 l: y! U, ^
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 : x( @$ U6 F8 F
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
# y3 U% |) b' P8 G6 S; s0 J% d
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 # g- S6 n1 u/ `2 ~& z3 j
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。, c  u# `2 B. Y
ALK一个指标医院要900多 ...
4 u' F1 U0 X& U  S$ `; Z  X& w
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
/ a1 @- a) S7 e# Y. O7 G  U
, B8 b$ q* d4 z现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表